%0 Journal Article
%A Berrocal, A
%A Arance, A
%A Castellon, V E
%A de la Cruz, L
%A Espinosa, E
%A Cao, M G
%A Larriba, J L G
%A Márquez-Rodas, I
%A Soria, A
%A Algarra, S M
%T SEOM clinical guideline for the management of malignant melanoma (2017).
%D 2017
%U http://hdl.handle.net/10668/11780
%X All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
%K Adjuvant
%K B-RAF
%K Immunotherapy
%K Melanoma
%K Metastatic
%~